After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going in 2026?

We examine Bristol Myers Squibb’s pipeline strategy and therapeutic priorities in 2026, as it faces a major patent cliff in ...

Explore 6 Maryland biotech companies with recent funding, ready to bring their breakthrough technologies to the clinic.

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

Explore neuroscience breakthroughs reshaping treatments for Alzheimer’s, Parkinson’s, PTSD, and other brain disorders.